← Back to Search

Suvorexant for Chronic Insomnia

Phase 4

Waitlist Available

Led By Jason Carter, PhD

Research Sponsored by Montana State University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 8 week

Awards & highlights

Study Summary

This trial will study whether the drug Suvorexant can help people with chronic insomnia by reducing sympathetic nerve activity and improving baroreflex function.

Eligible Conditions

Chronic Insomnia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 8 week

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~8 week

This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 week for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Baroreflex sensitivity

Sympathetic nerve activity

Secondary outcome measures

Home sleep quality: Wrist actigraphy

Laboratory sleep quality: Polysomnography

Sympathetic reactivity

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Drug (Suvorexant)Experimental Treatment1 Intervention

20 mg of Suvorexant daily (taken orally ~1 hour before bedtime)

Group II: PlaceboPlacebo Group1 Intervention

20 mg of Placebo daily (taken orally ~1 hour before bedtime)

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Suvorexant

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Montana State UniversityLead Sponsor

44 Previous Clinical Trials

1,043,810 Total Patients Enrolled

University of ChicagoOTHER

1,001 Previous Clinical Trials

817,696 Total Patients Enrolled

Jason Carter, PhDPrincipal InvestigatorMontana State University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How secure is the use of Suvorexant for individuals?

"Suvorexant is a proven and approved medication, so it scored 3 on our teams' assessment scale."

Answered by AI

Are there opportunities for participants to join this clinical investigation?

"This clinical trial is still recruiting, as indicated by the latest updates reflected on clinicaltrials.gov that date back to April 18th 2019 and October 5th 2021 respectively."

Answered by AI

Who meets the criteria to be an eligible participant in this trial?

"To meet the criteria of this trial, potential participants must experience insomnia and be in their late teens to early sixties. Approximately 34 individuals will be accepted into the experiment."

Answered by AI

Would this study accept applicants aged 18 and above?

"Patients aged between 18 and 65 years old are eligible to join this medical study."

Answered by AI

Could you elaborate on previous research that has been done concerning Suvorexant?

"Presently, 14 tests have been conducted with Suvorexant, two of which are in the final phase. Primarily centred around Silver Spring, Maryland there are 71 places conducting trials for this drug."

Answered by AI

How many participants are being incorporated into this trial?

"Correct. According to the data available at clinicaltrials.gov, this research project is currently enrolling candidates and was initially posted on April 18th 2019. The team managing the study requires 34 participants from a single site before they can move forward with their work."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia

2019. "Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03768713.

All > Insomnia > Belsomra